Arcutis Biotherapeutics, Inc.
ARQT
$31.19
$1.234.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 21.74% | 27.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 21.74% | 23.78% | |||
| Cost of Revenue | 15.92% | -15.15% | |||
| Gross Profit | 22.32% | 29.81% | |||
| SG&A Expenses | -9.78% | 8.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.64% | 6.35% | |||
| Operating Income | 158.35% | 40.43% | |||
| Income Before Tax | 148.19% | 37.27% | |||
| Income Tax Expenses | -76.61% | 22.58% | |||
| Earnings from Continuing Operations | 146.64% | 36.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 146.64% | 36.61% | |||
| EBIT | 158.35% | 40.43% | |||
| EBITDA | 164.00% | 33.63% | |||
| EPS Basic | 146.44% | 37.07% | |||
| Normalized Basic EPS | 147.97% | 37.75% | |||
| EPS Diluted | 146.44% | 37.07% | |||
| Normalized Diluted EPS | 146.01% | 37.75% | |||
| Average Basic Shares Outstanding | 0.49% | 0.76% | |||
| Average Diluted Shares Outstanding | 4.64% | 0.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||